US 11,944,600 B2
Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
Benjamin Whalley, Histon (GB); William Hind, Histon (GB); Royston Gray, Histon (GB); Javier Fernandez-Ruiz, Histon (GB); Eva De Lago, Madrid (ES); Carmen Rodriguez-Cueto, Madrid (ES); Laura Garcia-Toscano, Madrid (ES); and Irene Santos-Garcia, Madrid (ES)
Assigned to GW Research Limited, Histon (GB)
Appl. No. 16/629,722
Filed by GW Research Limited, Histon (GB)
PCT Filed Jul. 10, 2018, PCT No. PCT/GB2018/051954
§ 371(c)(1), (2) Date Jan. 9, 2020,
PCT Pub. No. WO2019/012267, PCT Pub. Date Jan. 17, 2019.
Claims priority of application No. 1711190 (GB), filed on Jul. 12, 2017.
Prior Publication US 2021/0077455 A1, Mar. 18, 2021
Int. Cl. A61K 31/353 (2006.01); A61K 31/00 (2006.01); A61K 31/05 (2006.01); A61K 31/192 (2006.01); A61K 31/575 (2006.01); A61K 36/185 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/658 (2023.05) [A61K 31/192 (2013.01); A61K 31/353 (2013.01); A61K 31/575 (2013.01); A61K 36/185 (2013.01); A61P 25/28 (2018.01)] 5 Claims
 
1. A method of treating a patient with amyotrophic lateral sclerosis (ALS) comprising administering to the patient tetrahydrocannabinol (THC) in combination with olesoxime.